ACTICOR BIOTECH: Presentation of Positive Results From the ACTIMIS Phase 1b/2a Study in Stroke at ESOC 2022
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical-stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies,announces today the